Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 32533590)

  • 1. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer.
    Hong CS; Sun EG; Choi JN; Kim DH; Kim JH; Ryu KH; Shim HJ; Hwang JE; Bae WK; Kim HR; Kim KK; Jung C; Chung IJ; Cho SH
    Cancer Sci; 2020 Sep; 111(9):3268-3278. PubMed ID: 32533590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
    Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
    Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
    Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
    Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
    Jhawer M; Goel S; Wilson AJ; Montagna C; Ling YH; Byun DS; Nasser S; Arango D; Shin J; Klampfer L; Augenlicht LH; Perez-Soler R; Mariadason JM
    Cancer Res; 2008 Mar; 68(6):1953-61. PubMed ID: 18339877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway.
    Lee HY; Crawley S; Hokari R; Kwon S; Kim YS
    Int J Oncol; 2010 Apr; 36(4):941-53. PubMed ID: 20198339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.
    Quintanal-Villalonga A; Molina-Pinelo S; Yagüe P; Marrugal Á; Ojeda-Márquez L; Suarez R; Ponce-Aix S; Enguita AB; Carnero A; Ferrer I; Paz-Ares L
    Lung Cancer; 2019 May; 131():112-121. PubMed ID: 31027687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
    Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
    Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphiregulin potentiates airway inflammation and mucus hypersecretion induced by urban particulate matter via the EGFR-PI3Kα-AKT/ERK pathway.
    Wang J; Zhu M; Wang L; Chen C; Song Y
    Cell Signal; 2019 Jan; 53():122-131. PubMed ID: 30291869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
    Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
    Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
    Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
    Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
    Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
    Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
    Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
    Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
    Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
    Yotsumoto F; Fukami T; Yagi H; Funakoshi A; Yoshizato T; Kuroki M; Miyamoto S
    Cancer Sci; 2010 Nov; 101(11):2351-60. PubMed ID: 20726858
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
    Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AREG mediates the epithelial‑mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF‑κB signalling pathway.
    Wang L; Wang L; Zhang H; Lu J; Zhang Z; Wu H; Liang Z
    Oncol Rep; 2020 May; 43(5):1558-1568. PubMed ID: 32323797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells.
    Cheng JC; Chang HM; Xiong S; So WK; Leung PC
    Oncotarget; 2016 Dec; 7(49):81645-81660. PubMed ID: 27835572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.